AMRESCO Inc. Names New President

AMRESCO Inc. Names New President

7/1/2013 7:24:18 AM

SOLON, Ohio, July 1, 2013 /PRNewswire/ -- AMRESCO, LLC, a leading manufacturer of biochemicals and reagents for the life science industry, announces Michael J. Mascali, RPh., has been named President of the Solon-based company.

Mr. Mascali joined AMRESCO as Vice President of Regulatory Affairs in May, 2006. He has managed the company's Quality Assurance, Quality Control, Regulatory Compliance, Continuous Improvement and Technical Services teams.

Prior to joining AMRESCO, Mr. Mascali served as Vice President of Pharmacy Operations for Marc Glassman, Inc., Senior Vice President of Operations for NEO-PET, LLC and most notably Senior Vice President for NCS Healthcare. He is a Fellow of the American Society of Consultant Pharmacists and an Advisory Board member of the Cuyahoga Community College Technician Program.


AMRESCO, LLC, a wholly-owned subsidiary of VWR International, LLC, is an ISO 13485, ISO 9001 and FDA registered biotech company. Founded in 1976, AMRESCO is a custom manufacturer and supplies high purity biochemicals and custom reagents for research in the diagnostic, molecular diagnostic, molecular biology and biopharmaceutical industries. AMRESCO's global distributor network consists of over 60 distributors represented in more than 50 countries.


Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.